Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Prolonged venetoclax (VEN) plus hypomethylating agent (HMA) therapy in non-promyelocytic AML: A single-centre retrospective cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

CCChen CaoXJXinwen Jiang

Discussion

Loading...

Member takes

Overview

Retrospective cohort study shows prolonged venetoclax therapy improves overall survival in AML, suggesting new treatment strategies.

Key Points

  • This analysis evaluates the impact of prolonged venetoclax therapy on progression-free survival and overall survival in AML patients.
  • Retrospective cohort study of 88 patients with newly diagnosed AML
  • Analyzed baseline characteristics and treatment outcomes over more than 4 cycles
  • Used Cox proportional hazards regression for survival analysis
  • 38.6% of patients relapsed during follow-up
  • 25.0% of patients died during follow-up
  • Age ≥ 60 years and TP53 mutation identified as significant adverse prognostic factors

Cite This Study

Cao et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e5b4https://doi.org/10.1182/blood-2025-6905
View Full Paper
Ask AI
Bookmark
Share